Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

469
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
469
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

903
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
903
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

757
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
757
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

426
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
426
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

639
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
639
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

702
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
702

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

PharmacoEconomics·2021
Same author

Developing a group intervention to manage fatigue in rheumatoid arthritis through modifying physical activity.

BMC musculoskeletal disorders·2019
Same author

Author Response: Patient Engagement.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2017
Same author

Coping Strategies, Psychological Impact, and Support Preferences of Men With Rheumatoid Arthritis: A Multicenter Survey.

Arthritis care & research·2017
Same author

Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients.

Rheumatology (Oxford, England)·2017
Same author

Development and testing of candidate items for inclusion in a new rheumatoid arthritis stiffness patient-reported outcome measure.

Rheumatology (Oxford, England)·2017
Same journal

Diabetic retinopathy: intravitreal vascular endothelial growth factor inhibitors for diabetic macular oedema.

BMJ clinical evidence·2016
Same journal

Subarachnoid haemorrhage (spontaneous aneurysmal).

BMJ clinical evidence·2016
Same journal

Malaria: fluid therapy in severe disease.

BMJ clinical evidence·2016
Same journal

Age-related macular degeneration: anti-vascular endothelial growth factor treatment.

BMJ clinical evidence·2016
Same journal

MRSA: treating people with infection.

BMJ clinical evidence·2016
Same journal

Trachoma.

BMJ clinical evidence·2016
See all related articles

Related Experiment Video

Updated: Mar 17, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.3K

Rheumatoid arthritis: previously untreated early disease.

Wiranthi M A Gunasekera1, John R Kirwan

  • 1Department of Rheumatology, Peterborough and Stamford NHS Foundation Trust, Peterborough, UK.

BMJ Clinical Evidence
|August 2, 2016
PubMed
Summary
This summary is machine-generated.

This systematic overview evaluates first-line treatments for rheumatoid arthritis, comparing various disease-modifying anti-rheumatoid drugs (DMARDs) and glucocorticoids. It identifies interventions likely to be beneficial for managing this chronic autoimmune condition.

More Related Videos

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
07:44

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Published on: July 14, 2023

1.8K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K

Related Experiment Videos

Last Updated: Mar 17, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.3K
Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
07:44

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Published on: July 14, 2023

1.8K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K

Area of Science:

  • Rheumatology and Immunology
  • Pharmacology and Therapeutics

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease causing symmetrical polyarthritis, primarily affecting hands and feet.
  • Current pharmacological treatments for RA include NSAIDs, glucocorticoids (GCs), and various disease-modifying anti-rheumatoid drugs (DMARDs), categorized as synthetic (conventional [csDMARDs] or targeted [tsDMARDs]) or biological (bDMARDs).

Purpose of the Study:

  • To systematically evaluate the comparative effectiveness and safety of different first-line treatment strategies for rheumatoid arthritis.
  • To answer specific clinical questions regarding the efficacy of methotrexate monotherapy versus combination therapy, biological DMARDs (bDMARDs) versus csDMARDs, bDMARDs in combination with methotrexate, and glucocorticoids in combination with methotrexate or csDMARDs.

Main Methods:

  • A systematic overview of existing evidence was conducted.
  • Searches were performed in Medline, Embase, The Cochrane Library, and other databases up to December 2014.
  • A GRADE evaluation was applied to 18 PICO (Population, Intervention, Comparison, Outcome) combinations.

Main Results:

  • The systematic search identified 2058 studies, with 10 systematic reviews, 22 RCTs, and one follow-up report added at this update.
  • Effectiveness and safety data for 22 comparisons involving bDMARDs, csDMARDs, GCs, and methotrexate were analyzed.
  • GRADE evaluations were performed to assess the quality of evidence for various treatment comparisons.

Conclusions:

  • The study categorized the efficacy of multiple first-line treatment options for rheumatoid arthritis.
  • Interventions were identified as likely or unlikely to be beneficial based on effectiveness and safety profiles.
  • This overview provides guidance on selecting initial therapies for patients with rheumatoid arthritis who have not previously undergone DMARD treatment.